All In Biotech

Drug Trial Radar · NCT01120028

Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy

Open-label, Randomised Multicentre Study of CAMPATH-1H Versus Basiliximab Induction Treatment and Sirolimus Versus Tacrolimus Maintenance Treatment for the Preservation of Renal Function in Patients Receiving Kidney Transplants

Last checked: Nov 20, 2026Latest source record: Apr 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 852 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

852

Actual

Start

Sep 2010

Primary completion

Feb 2014

Study completion Mar 2020

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Health Service, United Kingdom; Pfizer; Novartis
First posted
May 10, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The 3C study is investigating whether reducing exposure to calcineurin inhibitors (by using more potent antibody induction treatment and/or an elective switch to sirolimus) can improve the function and survival of kidney transplants.

Conditions

  • Kidney Transplantation

Interventions

  • AlemtuzumabDrug

    Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart

  • BasiliximabDrug

    20 mg intravenously, two doses 96 hours apart

  • SirolimusDrug

    Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL

  • TacrolimusDrug

    Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction TherapyTime frame: 6 months post-transplantation
  2. Graft Function (at 18-months After Randomization to Maintenance Therapy)Time frame: 2 years post-transplantation

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Addenbrooke's Hospital NHS Trust

    Cambridge, United Kingdom

  • University Hospital of Wales

    Cardiff, United Kingdom

  • University Hospitals Coventry & Warwickshire

    Coventry, United Kingdom

  • Royal Infirmary

    Edinburgh, United Kingdom

  • Western Infirmary

    Glasgow, United Kingdom

  • Hull and East Yorkshire Hospitals NHS Trust

    Hull, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

  • Royal Liverpool and Broadgreen University Hospitals NHS Trust

    Liverpool, United Kingdom

  • Bart's and the London NHS Trust

    London, United Kingdom

  • Guy's and St Thomas's NHS Trust

    London, United Kingdom

  • Kings College Hospital NHS Trust

    London, United Kingdom

  • Royal Free Hampstead NHS Trust

    London, United Kingdom

  • Central Manchester NHS Trust

    Manchester, United Kingdom

  • Newcastle-upon-Tyne Hospitals NHS Trust

    Newcastle, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

  • Plymouth Teaching Hospitals NHS Trust

    Plymouth, United Kingdom

  • Portsmouth Hospitals NHS Trust

    Portsmouth, United Kingdom

  • Sheffield Teaching Hospitals NHS Trust

    Sheffield, United Kingdom

  • Oxford Radcliffe Hospitals NHS Trust

    Oxford, Oxon, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.